We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of... Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result. Show more
Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA...
ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a...
Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics Natera, Inc. (NASDAQ:...
Data demonstrates that MIBC patients who remain Signatera MRD-negative after surgery may be spared from adjuvant treatment, with 100% overall survival at 12 months Natera, Inc. (NASDAQ: NTRA), a...
First of its kind study in muscle-invasive urothelial cancer, with both escalation and de-escalation arms Approximately 1,000 patients will be enrolled at more than 300 sites Natera, Inc...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the...
Supports broader adoption of Natera’s RenasightTM test Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.86 | 2.0749665328 | 89.64 | 93.64 | 83.13 | 1368986 | 87.92932097 | CS |
| 4 | 1.28 | 1.41875415651 | 90.22 | 98.82 | 83.13 | 1222767 | 91.94782658 | CS |
| 12 | 24.92 | 37.4286572544 | 66.58 | 98.82 | 64.74 | 1432484 | 85.28160865 | CS |
| 26 | 51.68 | 129.784028127 | 39.82 | 98.82 | 36.9 | 1430224 | 70.20368094 | CS |
| 52 | 38.59 | 72.9351729352 | 52.91 | 98.82 | 36.9 | 1267298 | 61.26859952 | CS |
| 156 | -20.62 | -18.3910096325 | 112.12 | 129.09 | 26.1 | 1333344 | 59.40524238 | CS |
| 260 | 72.65 | 385.411140584 | 18.85 | 129.09 | 16.87 | 1102544 | 58.08579682 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
